Literature DB >> 16186601

Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice.

Elyisha A Hanniman1, Gilles Lambert, Tanya C McCarthy, Christopher J Sinal.   

Abstract

The farnesoid X receptor (FXR) is a bile acid-activated transcription factor that regulates the expression of genes critical for bile acid and lipid homeostasis. This study was undertaken to investigate the pathological consequences of the loss of FXR function on the risk and severity of atherosclerosis. For this purpose, FXR-deficient (FXR-/-) mice were crossed with apolipoprotein E-deficient (ApoE-/-) mice to generate FXR-/- ApoE-/- mice. Challenging these mice with a high-fat, high-cholesterol (HF/HC) diet resulted in reduced weight gain and decreased survival compared with wild-type, FXR-/-, and ApoE-/- mice. FXR-/- ApoE-/- mice also had the highest total plasma lipids and the most atherogenic lipoprotein profile. Livers from FXR-/- and FXR-/- ApoE-/- mice exhibited marked lipid accumulation, focal necrosis (accompanied by increased levels of plasma aspartate aminotransferase), and increased inflammatory gene expression. Measurement of en face lesion area of HF/HC-challenged mice revealed that although FXR-/- mice did not develop atherosclerosis, FXR-/- ApoE-/- mice had approximately double the lesion area compared with ApoE-/- mice. In conclusion, loss of FXR function is associated with decreased survival, increased severity of defects in lipid metabolism, and more extensive aortic plaque formation in a mouse model of atherosclerotic disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16186601     DOI: 10.1194/jlr.M500390-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  51 in total

1.  Upregulation of decorin by FXR in vascular smooth muscle cells.

Authors:  Fengtian He; Qiuhong Zhang; Ramalinga Kuruba; Xiang Gao; Jiang Li; Yong Li; Wei Gong; Yu Jiang; Wen Xie; Song Li
Journal:  Biochem Biophys Res Commun       Date:  2008-06-02       Impact factor: 3.575

2.  Conformational dynamics of human FXR-LBD ligand interactions studied by hydrogen/deuterium exchange mass spectrometry: insights into the antagonism of the hypolipidemic agent Z-guggulsterone.

Authors:  Liping Yang; David Broderick; Yuan Jiang; Victor Hsu; Claudia S Maier
Journal:  Biochim Biophys Acta       Date:  2014-06-18

3.  Suppressing the intestinal farnesoid X receptor/sphingomyelin phosphodiesterase 3 axis decreases atherosclerosis.

Authors:  Qing Wu; Lulu Sun; Xiaomin Hu; Xuemei Wang; Feng Xu; Bo Chen; Xianyi Liang; Jialin Xia; Pengcheng Wang; Daisuke Aibara; Shaofei Zhang; Guangyi Zeng; Chuyu Yun; Yu Yan; Yicheng Zhu; Michael Bustin; Shuyang Zhang; Frank J Gonzalez; Changtao Jiang
Journal:  J Clin Invest       Date:  2021-05-03       Impact factor: 14.808

Review 4.  Bile acids regulate cardiovascular function.

Authors:  Sandeep Khurana; Jean-Pierre Raufman; Thomas L Pallone
Journal:  Clin Transl Sci       Date:  2011-06       Impact factor: 4.689

5.  Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice.

Authors:  Helen B Hartman; Stephen J Gardell; Chris J Petucci; Shuguang Wang; Julie A Krueger; Mark J Evans
Journal:  J Lipid Res       Date:  2009-01-27       Impact factor: 5.922

6.  Alterations of Cholesterol Metabolism in Inflammation-Induced Atherogenesis.

Authors:  David P Hajjar; Katherine A Hajjar
Journal:  J Enzymol Metab       Date:  2016-05-31

7.  FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver.

Authors:  Romeo Papazyan; Xueqing Liu; Jingwen Liu; Bin Dong; Emily M Plummer; Ronald D Lewis; Jonathan D Roth; Mark A Young
Journal:  J Lipid Res       Date:  2018-03-20       Impact factor: 5.922

8.  The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria.

Authors:  Xiaoxin X Wang; Tao Jiang; Yan Shen; Luciano Adorini; Mark Pruzanski; Frank J Gonzalez; Pnina Scherzer; Linda Lewis; Shinobu Miyazaki-Anzai; Moshe Levi
Journal:  Am J Physiol Renal Physiol       Date:  2009-09-23

9.  Farnesoid X receptor-Acting through bile acids to treat metabolic disorders.

Authors:  Yanqiao Zhang
Journal:  Drugs Future       Date:  2010-08-01       Impact factor: 0.148

10.  The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice.

Authors:  Andrea Mencarelli; Sabrina Cipriani; Barbara Renga; Daniela Francisci; Giuseppe Palladino; Eleonora Distrutti; Franco Baldelli; Stefano Fiorucci
Journal:  PLoS One       Date:  2010-10-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.